Standout Papers
- An Algorithm for the Grading of Activity in Chronic Hepatitis C (1996)
- Natural history of liver fibrosis progression in patients with chronic hepatitis C (1997)
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis C (2003)
- Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C (1994)
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2019)
- Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients (2012)
- Fibrosis in Human Adipose Tissue: Composition, Distribution, and Link With Lipid Metabolism and Fat Mass Loss (2010)
- Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease (2014)
- A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer (2016)
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver (2013)
- Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH (2023)
- Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening (2020)
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024)
- Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort (2021)
- Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023)
- Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study (2023)
- Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial (2024)
Immediate Impact
5 by Nobel laureates 9 from Science/Nature 145 standout
Citing Papers
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
2024 Standout
Works of Pierre Bédossa being referenced
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
2023 Standout
Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients
1988
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Pierre Bédossa | 27273 | 21759 | 5455 | 506 | 37.5k | |
| Zachary Goodman | 32446 | 30336 | 4296 | 293 | 40.9k | |
| Massimo Pinzani | 16642 | 15481 | 5471 | 325 | 26.2k | |
| David E. Kleiner | 31134 | 17152 | 7096 | 510 | 49.1k | |
| Frank Tacke | 21618 | 15955 | 6060 | 695 | 43.6k | |
| Valérie Paradis | 12909 | 11714 | 5429 | 430 | 24.2k | |
| Adrian M. Di Bisceglie | 23266 | 23261 | 2203 | 380 | 32.6k | |
| Ramón Bataller | 15823 | 11822 | 4037 | 302 | 24.7k | |
| Michael Torbenson | 12360 | 8972 | 3876 | 292 | 22.2k | |
| Elizabeth M. Brunt | 38092 | 17176 | 8692 | 268 | 48.9k | |
| Stefan Zeuzem | 32059 | 33445 | 3983 | 1.0k | 45.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...